文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Electrotherapy as treatment for chemotherapy-induced peripheral neuropathy - a randomized controlled trial.

作者信息

Sassmann Robert, Gampenrieder Simon Peter, Rieder Florian, Johansson Tim, Rinnerthaler Gabriel, Castagnaviz Vanessa, Lampl Kathrin, Herfert Jürgen, Kienberger Yvonne Theres, Flamm Maria, Schaffler-Schaden Dagmar, Greil Richard

机构信息

Institute of Physical Medicine and Rehabilitation, Paracelsus Medical University Salzburg, Salzburg, Austria.

IIIrd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.

出版信息

Front Neurol. 2024 Dec 24;15:1451456. doi: 10.3389/fneur.2024.1451456. eCollection 2024.


DOI:10.3389/fneur.2024.1451456
PMID:39777312
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11704885/
Abstract

BACKGROUND: Electrotherapy has been investigated in chronic pain and diabetic peripheral neuropathy, however prospective trials in patients with chemotherapy-induced peripheral neuropathy (CIPN) are scarce. METHODS: Fifty-one patients with CIPN ≥ grade 1 subsequent to receiving platinum- and/or taxane-based chemotherapy types were randomized to 8 weeks of high tone external muscle stimulation (HTEMS) or transcutaneous electrical nerve stimulation (TENS). The primary outcome were changes in the EORTC-QLQ-CIPN20 questionnaire. Secondary outcomes included clinical examinations, a classification of CIPN according to CTCAE v 4 and the EORTC-QLQ-C30 questionnaire. A control group (n = 17) receiving no intervention was recruited retrospectively. RESULTS: The EORTC-QLQ-CIPN20 sensory and motor scales improved in both intervention groups (TENS: -12.3pts and - 8.2pts; HTEMS: -14.7pts and - 8.2pts) with no significant changes in the control group -3.3pts; -2.8pts. The changes in the sensory scale differed significantly between the HTEMS and the control group. In the EORTC-QLQ-C30 questionnaire, there was a significant improvement for physical functioning in the HTEMS group only (+7.9pts) with no between group differences. CIPN classification according to CTCAE v4 improved significantly in both intervention groups. CONCLUSION: Home-based electrotherapy with HTEMS or TENS were successful in improving CIPN-related sensory impairment and could therefore provide a powerful treatment for this side-effect of chemotherapy. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/ct2/show/NCT03978585.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff51/11704885/bdfeadfbc8da/fneur-15-1451456-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff51/11704885/31d40a0869f6/fneur-15-1451456-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff51/11704885/6f8da425e301/fneur-15-1451456-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff51/11704885/bdfeadfbc8da/fneur-15-1451456-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff51/11704885/31d40a0869f6/fneur-15-1451456-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff51/11704885/6f8da425e301/fneur-15-1451456-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff51/11704885/bdfeadfbc8da/fneur-15-1451456-g003.jpg

相似文献

[1]
Electrotherapy as treatment for chemotherapy-induced peripheral neuropathy - a randomized controlled trial.

Front Neurol. 2024-12-24

[2]
[Electroacupuncture for the prevention of chemotherapy-induced peripheral neuropathy: a randomized controlled trial].

Zhongguo Zhen Jiu. 2024-12-12

[3]
Comparison of high tone therapy and transcutaneous electrical nerve stimulation therapy in chemotherapy-induced polyneuropathy.

Medicine (Baltimore). 2020-5

[4]
Wireless Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Proof-of-Concept Randomized Clinical Trial.

J Pain. 2024-5

[5]
Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors.

J Patient Rep Outcomes. 2021-9-26

[6]
Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).

Asia Pac J Clin Oncol. 2019-2

[7]
Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.

Support Care Cancer. 2017-11

[8]
Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.

J Natl Compr Canc Netw. 2023-2

[9]
Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy.

Support Care Cancer. 2019-4-10

[10]
Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population.

Eur J Cancer. 2016-12

引用本文的文献

[1]
Combined Exercise Therapy and Alternating Magnetic Field Therapy for Chemotherapy-Induced Peripheral Neuropathy in a Rectal Cancer Survivor: A Case Report.

Cureus. 2025-8-2

[2]
Influence of photobiomodulation on sensory symptoms, balance, and gait speed in chemotherapy-induced peripheral neuropathy.

Support Care Cancer. 2025-4-5

本文引用的文献

[1]
Home-based high tone therapy may alleviate chemotherapy-induced neuropathic symptoms in patients with colorectal cancer: A randomized double-blind placebo-controlled pilot evaluation.

Support Care Cancer. 2024-1-27

[2]
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

N Engl J Med. 2022-1-27

[3]
Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy.

Int J Environ Res Public Health. 2021-5-26

[4]
The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients.

J Cancer Surviv. 2021-4

[5]
Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study.

J Clin Med. 2020-7-27

[6]
Comparison of high tone therapy and transcutaneous electrical nerve stimulation therapy in chemotherapy-induced polyneuropathy.

Medicine (Baltimore). 2020-5

[7]
A systematic review and meta-analysis of the efficacy of acupuncture and electroacupuncture against chemotherapy-induced peripheral neuropathy.

Medicine (Baltimore). 2020-4

[8]
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.

Oncologist. 2020-2

[9]
Prevention and Management of Chemotherapy-Induced Polyneuropathy.

Breast Care (Basel). 2019-4

[10]
Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial.

Support Care Cancer. 2019-6-17

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索